GATC Health Presents at the 38th Annual Southern California Society of Toxicology Fall Meeting
IRVINE, Calif., October 14, 2026 – GATC Health’s Robert Tinder, Ph.D., Head of Chemical Research and Development, alongside Senior Scientist Dhanaji Lade, Ph.D., and Research Operations Associate Tarsh Shah, recently presented their abstract, “Metabolite ratios, not metabolite identity, guide non-NHP species selection: a case study with GATC-1021,” at the 38th Annual SCCSOT Meeting in Carlsbad, California.
(L to R): Dhanaji Lade, Ph.D., Robert Tinder, Ph.D., Tarsh Shah, and Bijay Shrestha, Ph.D.
The event’s theme of “AI-Enabled Toxicology” provided an opportunity to showcase GATC Health’s AI-driven predictive modeling capabilities for early drug safety assessments. During the session, they engaged directly with top pharmaceutical stakeholders and regulatory agencies. This successful presentation validated our technology and further positioned us at the forefront of modernizing traditional toxicology methods.
About GATC
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating novel intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.
Contact Us
Similar News
Science Behind GATC-1021 Featured in Physicians Weekly
June 19, 2026 — A new feature in Physician’s Weekly explores the clinical science behind the discovery of GATC-1021, a…
Read more
CTO Jayson Uffens Explains GATC Health’s AI Breakthrough
June 5, 2026 — In “Building a Biological Intelligence Layer for Drug Discovery,“ GATC Health CTO and co-founder, Jayson Uffens…
Read more
GATC Health Receives Concentrated Media Visibility Across AI, Capital Markets and Regulatory Policy Conversations
April 7, 2026 — GATC Health received a strong run of media attention over the past two weeks, with six notable inclusions across BioSpace a…
Read more